



Ref: SEC/SE/2021-22

Date: March 25, 2022

To,
Corporate Relations Department
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block, Bandra – Kurla
Complex, Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol - DABUR

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Appointment of Alternate Director

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the Listing Regulations, we wish to inform you that the Board of Directors of the Company has, in its meeting held today i.e. on March 25, 2022, based on the recommendation of Nomination and Remuneration Committee, appointed Dr. Anand Chand Burman (DIN: 00056216) as an alternate director to Mr. Amit Burman, Non-Executive Director, w.e.f. March 25, 2022.

Brief profile and other requisite details of Dr. Anand Chand Burman have been given in the Annexure 1, as required under Regulation 30 of the Listing Regulations.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For **Dabur India Limited**


(A K Jain)
Executive V P (Finance) and Company Secretary



Encl: A/a

Dr. Anand Chand Burman (DIN: 00056216)

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment as an alternate director to Mr. Amit Burman, Non-Executive Director.
2.	Date of appointment / cessation (as applicable) & term of appointment	Dr. Burman's appointment as an alternate director is effective March 25, 2022 and shall come to an end upon return of Mr. Amit Burman to India or expiry of tenure of Mr. Amit Burman as a Director, whichever is earlier.
3.	Brief profile	<p>Dr. Anand C. Burman is the honorary advisor to the Board of Dabur India Ltd, one of India's leading consumer goods companies with presence in over 100 countries across the globe. Dr. Burman is a trained pharmacist and is widely recognized for his interests in Research & Development that has helped him earn over 40 patents in his name.</p> <p>Dr. Burman has particular interests in the areas of R&D in Pharmaceutical Sciences as well as Biotechnology and Technology issues. His education was both multidisciplinary and international. He completed his high school education from St. Paul's School in Darjeeling, India and followed it with a B.Sc. in Chemistry from the University of Wisconsin and M.Sc. in Chemistry from the University of Kansas. His Doctorate was in the area of Pharmaceutical Chemistry from the University of Kansas in 1980.</p> <p>Dr. Burman is a member of the fifth generation of Dabur group's founder family and took charge as the Chairman of Dabur India Ltd. in 2007 after holding the post of Vice-chairman and having been associated with the company in various other roles. His interests in R&D closely align with Dabur's focus on developing products that offer holistic wellness, and spearheaded Dabur's transformation from an Ayurvedic medicines maker to becoming India's 4th largest FMCG (Fast Moving Consumer Goods) player. He also serves as Director on the Board of Dabur International Ltd., Dabur Research Foundation, Dabur (UK) Ltd., H&B Stores Ltd., among others. He stepped down as the Chairman of Dabur India Ltd. in 2019.</p>



Sl. No.	Particulars	Details
		<p>Other than the Dabur Group Companies, he is also on the Board of Aviva Life Insurance, Ester Industries Limited, etc. In addition, he is a member of the Advisory Board of the Institute for Advancing Medical Innovation under the University of Kansas, USA.</p> <p>Dr. Burman is the recipient of numerous awards and honors, including the Ernst & Young Entrepreneur Of The Year award in 2011.</p>
4.	Disclosure of relationship between directors of the Company	Dr. Burman is father of Mr. Aditya C. Burman, Non-Executive Director of the Company.
5.	Information as required under Circular No. LIST/COMP/14/2018- 19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively.	He is not debarred from holding the office of a Director by virtue of any Order of SEBI or any other such Authority.

28

